Share on StockTwits

Medivation (NASDAQ:MDVN) Insider Lynn Seely unloaded 20,000 shares of the stock in a transaction that occurred on Wednesday, August 27th. The shares were sold at an average price of $89.42, for a total transaction of $1,788,400.00. Following the transaction, the insider now directly owns 59,022 shares in the company, valued at approximately $5,277,747. The sale was disclosed in a document filed with the SEC, which is available at this link.

MDVN has been the subject of a number of recent research reports. Analysts at Zacks reiterated a “neutral” rating on shares of Medivation in a research note on Monday. They now have a $89.00 price target on the stock. Separately, analysts at Jefferies Group reiterated a “positive” rating on shares of Medivation in a research note on Monday, August 18th. Finally, analysts at Aegis raised their price target on shares of Medivation from $125.00 to $130.00 in a research note on Friday, August 8th. One analyst has rated the stock with a sell rating, six have given a hold rating and eight have issued a buy rating to the company’s stock. Medivation currently has a consensus rating of “Hold” and an average target price of $97.00.

Medivation (NASDAQ:MDVN) traded up 0.04% during mid-day trading on Thursday, hitting $89.48. The stock had a trading volume of 785,925 shares. Medivation has a one year low of $48.15 and a one year high of $91.04. The stock has a 50-day moving average of $79.43 and a 200-day moving average of $72.46. The company has a market cap of $6.871 billion and a price-to-earnings ratio of 287.59.

Medivation (NASDAQ:MDVN) last posted its quarterly earnings results on Thursday, August 7th. The company reported $0.60 EPS for the quarter, beating the Thomson Reuters consensus estimate of $0.24 by $0.36. The company had revenue of $148.09 million for the quarter, compared to the consensus estimate of $126.46 million. During the same quarter in the prior year, the company posted ($0.07) earnings per share. The company’s quarterly revenue was up 111.1% on a year-over-year basis. Analysts expect that Medivation will post $2.43 earnings per share for the current fiscal year.

Medivation, Inc is a biopharmaceutical company focused on the development and commercialization of novel therapies.

Receive News & Ratings for Medivation Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medivation Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.